PANELISTS


Deborah Blacker
MD, ScD
Dr. Blacker is a geriatric psychiatrist and epidemiologist who directs the Gerontology Research Unit at Massachusetts General Hospital, where she also serves as co-director of the Clinical Core for the Mass Alzheimer's Disease Research Center and Assistant Vice Chair for Research in the Department of Psychiatry. She is Associate Professor of Psychiatry at Harvard Medical School. She is also actively involved in teaching and methodologic research at the Harvard School of Public Health, where she directs the Psychiatric Epidemiology concentration, and is Associate Professor in Epidemiology. Her primary work is aimed at locating genes that contribute to risk for Alzheimer's disease, including several different projects to collect, evaluate, and follow clinical samples for the study of Alzheimer's genetics. She is also involved in studies aimed at early recognition of Alzheimer's disease using clinical, neuropsychological, and neuroimaging methods, and understanding the genetic and environmental risk factors affecting the transition from mild memory difficulties to dementia. She serves on the American Psychiatric Association’s (APA) work group to revise the Practice Guidelines for Dementia, the APA’s DSM-V Neurocognitive Disorders Work Group, the Board of Directors of the Massachusetts and New Hampshire Alzheimer’s Association, and on multiple research advisory boards.

Dr. Blacker received her bachelor’s degrees from Stanford University and her medical degree from Harvard Medical School. She completed her psychiatric residency at Massachusetts General Hospital in Boston, after which she completed her doctorate in Epidemiology at the Harvard School of Public Health.


Dr. Frédéric Checler
MD
Frédéric Checler is PhD in Molecular and Cellular Biology and Research Director at the National Institute of Health and Medical Research (INSERM). He is heading the group of Cellular and Molecular Biology of Normal and Pathological Cerebral Aging at Sophia-Antipolis,Valbonne, France. His main research interests concern Alzheimer’s, Parkinson’s and Prion’s diseases with special emphasis on the proteolytic dysfunctions taking place in these diseases and molecular alterations in the control of cell death. Frédéric Checler was among the very first to link proteasome dysfunction to AD pathology and noticeably, p53 to the function of members of the γ-secretase complex. He was also first to show that it was possible to inhibit Aβ production without affecting Notch cleavage and that there could exist PS-independent γ-secretase-like activity. Furthermore, F. Checler’s team evidenced a novel mechanism by which the APP metabolite AICD could control neprilysin and p53 at a transcriptional level. Finally, F. Checler’s team recently unraveled a novel function for parkin as a transcriptional repressor of p53.

Frédéric Checler is PI of several research national and European grants. Dr. Checler is President of the scientific committee of the European League against Alzheimer’s Disease (LECMA), member of the scientific committees of the Mediterranean Neuropôle, the Neuropôle Francilien and France Alzheimer. He has been recently appointed by the President of the French Republic as coordinator of the physiopathological aspects of the French Alzheimer’s plan and now is one of the French members of the “comité opérationnel” of the scientific cooperation foundation driving the French Alzheimer’s plan. Frédéric Checler is deputy Chief Editor of Journal of Neurochemistry, European Editor of Current Alzheimer research, member of the editorial board of the Journal of Biological chemistry and reviewer of more than 20 journals. He is currently member of the ASBMB, the Society for Neuroscience, the French Society for Neuroscience, the Society for Neurochemistry. He has been invited as speaker in several International Conferences on Alzheimer’s Diseases and related disorders, AD/PD international meetings and Springfield congresses and in 27 international congresses these last three years. He has published 190 peer reviewed papers and has been awarded by the Biomerieux award, 1999 MHRI Kearney fellow award and Charles Louis Saulces de Freycinet award from the French Academy of Science.


Pr. Bruno Dubois
MD
Bruno Dubois is currently Professor of Neurology at the Neurological Institute of the University Salpetriere Hospital in Paris. He is Director of the Cognitive Neurology Department and of the Alzheimer’s Center at the Hospital. He is also Director of the Research Unit Inserm U-610 and member of the Institute of Neurosciences of the University Pierre et Marie Curie Paris6. He is President of the Scientific Committee of France-Alzheimer and of IFRAD (International Fund Raising for Alzheimer’s disease), consultant for the Human Frontier Program and Expert of the French Agency of Drugs. He is a member of the European Alzheimer Disease Consortium (Therapeutics and Intervention Studies). He has published on anatomical and biochemical studies on the central cholinergic systems in rodents and humans; on cognitive neuropharmacology; and on neuropsychology in patients with dementia, with special reference to memory and executive functions. He recently organized an Expert Consensus on the new criteria for Alzheimer’s disease and a Task Force on the new criteria for Parkinson’s disease dementia. He is principal or co-investigator of a number of research programmes focusing on AD, MCI and dementia in Parkinson’s disease.


Pr. Bradley Hyman
MD, PhD
Dr Hyman is the John B Penney Jr Chair and Professor of Neurology at Harvard Medical School and Massachusetts General Hospital. He moved to Harvard/MGH in 1989, following MD. Phd, Neurology residency, Chief Residency, and fellowships in neuropathology and behavioral neurology at the University of Iowa. Dr Hyman's clinical and research focus has been on dementias, and he now directs the Massachusetts Alzheimer Disease Research Center at MGH. His research has focused on neuropathological underpinnings of memory disturbances in dementia, and has emphasized the use of animal models and novel imaging technologies including multiphoton microscopy. His work has been recognized by a Met Life Award, a Potamkin prize, the Alzheimer Association Zenith and Pioneer awards, and an NIH Merit award.


Stephane Lehericy
MD, PhD
 
Stephane Lehericy is professor of Neuroradiology and director of the Center for NeuroImaging Research (CENIR) at Pitié-Salpêtrière Hospital, Paris. He is also in charge of MRI affairs for the French Society of Radiology (SFR) since 2008
 
 
 
Chester A. Mathis
Ph.D
Chester A. Mathis, Ph.D., is Professor of Radiology, Pharmacology, and Pharmaceutical Sciences at the University of Pittsburgh, Director of the University of Pittsburgh Positron Emission Tomography (PET) Facility, and the inaugural holder of the UPMC PET Research Endowed Chair. Dr. Mathis has a long standing interest in applying synthetic radiochemistry techniques to develop PET radiopharmaceuticals to study brain function in vivo. Over the past 25 years, he has focused primarily on the development of radiotracers to image neuroreceptor systems, as well as agents to evaluate other aspects of normal and abnormal function of the central nervous system using PET imaging methodology. Approximately 15 years ago, Dr. Mathis joined efforts with Dr. William E. Klunk of the Department of Psychiatry at the University of Pittsburgh to devise a PET radiotracer capable of imaging amyloid-beta plaques in living human brain. This work led to the development of Pittsburgh Compound-B (PiB) to non-invasively assess amyloid-beta plaque load in the brains of humans using PET imaging. The PiB compound is currently used to image amyloid-beta in human brain at more than 70 PET Centers throughout the world and more than 10,000 PIB PET studies have been conducted to date. Dr. Mathis was awarded the 2004 MetLife Foundation Award for Medical Research in Alzheimer's disease, the 2008 Potamkin Award from the American Academy of Neurology, the 2009 Ronald and Nancy Reagan Research Award from the Alzheimer’s Association, the 2009 Kuhl-Lassen Brain Imaging Award and the 2010 Paul C. Aebersold award from the Society of Nuclear Medicine for basic imaging research and successful use of PiB for amyloid plaque imaging.
Pr. Guy McKhann
MD
 
Information will be added soon


Pr. Jean-Marc Orgogozo
MD, PhD
Graduated as an MD in 1975 from the University of Bordeaux, France, and qualified as a Neurologist in 1977 after fellowships at La Salpêtrière Hospital in Paris and in Bispebjerg Hospital in Copenhagen. He is currently Head of the Clinical Neurosciences Division at the University Hospital and Professor of Neurology at the University of Bordeaux. Among other international responsibilities, he is past-Chairman of the European Stroke Council (ESC) and of the European Union Affairs Committee of the European Federation of Neurological Societies (EFNS), past-officer of the European Stroke Initiative and past member of the Membership Committee of the American Academy of Neurology. He serves as an Expert in Neurology to the World Health Organization (WHO), for which he was responsible for the Neurological Adaptation of the WHO International Classification of Diseases-10. After having been a member of the French Drug Registration Agency «Commission d’AMM» for three years, he serves as an expert for cerebrovascular disease and dementia trials to the EMEA. At the request of the French Agency, Rapporteur, he drafted the guidelines for dementia trials which were issued by the EMEA/CPMP in Sept. 1997 and contributed to the «Points to Consider» for acute stroke trials.

Pr Orgogozo is the Chairman of the Steering Committee of the International Working Group Harmonization for Dementia Trials, for which he co-organized since 2001 five Asian regional meetings on concepts, methods and instruments in dementia and MCI research. He is or was on the Editorial Boards of Stroke, Neuroepidemiology, Annales de Cardiologie et d'Angéiologie, Dementia, European Journal of Neurology and Cerebrovascular Diseases. He has published over 300 articles on various neurological subjects, particularly on clinical trials for the treatment of cerebrovascular disease and dementia, with a special interest in the aging brain, the epidemiology of dementia and the neuropsychology of dementia.


Dr. Sudha Seshadri
BBS, MD, DM
Dr. Sudha Seshadri is a board certified neurologist who is currently serving as an Associate Professor of Neurology at the Boston University School of Medicine. She is a Senior Investigator at the Framingham Heart Study where she heads the Clinical Neurology and Neurogenetics Cores.

She completed her Medical Training (MBBS) in India from the Christian Medical College, Vellore and the Madras Medical College of Madras University, and her MD in Internal Medicine and DM in Neurology from the All India Institute of Medical Sciences, New Delhi. Additionally, she completed a Residency in Neurology at the Boston University School of Medicine and Fellowships in the Neurobiology of Aging at the University of Massachusetts Medical Center and in Neuroepidemiology at the Framingham Heart Study. She has previously worked as Assistant Professor of Neurology at the All India Institute of Medical Sciences, New Delhi and at the Sree Chitra Thirunal Institute of Medical Sciences and Technology in Trivandrum, Kerala. She joined the Boston University School of Medicine's Department of Neurology faculty in May 2001 where her responsibilities include outpatient and inpatient clinical care (Alzheimer’s disease, dementia and general neurology), teaching, mentoring and research. She also leads the neurology phenotype working group within the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium.

Her research has focused on 5 interrelated areas: (a) the epidemiology of dementia and Alzheimer’s disease (AD), pre-MCI and MCI (mild cognitive impairment) as life course diseases whose risk is determined by genomic variation, epigenetic, early, mid- and late-life exposures. (b) the role of lifestyle and modifiable risk factors in determining risk of dementia and AD, (c) the possible biological underpinnings of the observed associations between lifestyle factors and the risk of AD including the study of adipokines and neural growth factors; (d) genomic variation underlying brain aging, stroke, Alzheimer’s disease and vascular cognitive impairment; and (e) The epidemiology of stroke, vascular cognitive impairment and normal brain aging.
 
 
 
Reisa Sperling
M.D., M.MSc
Reisa Sperling is a neurologist, specializing in dementia and imaging research. She is an Associate Professor in Neurology at Harvard Medical School. Dr. Sperling is the Director of the new Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital and serves as the Director of the Alzheimer’s disease Neuroimaging Program of the Massachusetts Alzheimer’s Disease Research Center. She is past chair of the Medical and Scientific Advisory Committee of the Massachusetts Chapter of the Alzheimer’s Association, and currently serves on the Steering Committee for the National Institutes of Health Alzheimer’s Disease Cooperative Study (ADCS) and Alzheimer’s Disease Neuroimaging Initiative (ADNI). Dr. Sperling is a standing member of the National Institute on Aging- Neuroscience of Aging (NIA-N) review committee.

Dr. Sperling’s research is focused on the early diagnosis and treatment of Alzheimer’s disease. Her recent work involves the use of functional MRI and PET amyloid imaging to study alterations in brain function during in aging and early Alzheimer’s disease. She is the Principal Investigator on multiple NIH and Foundation grants to study the neural basis of memory impairment in MCI and AD, and the relationship of amyloid deposition to memory function, including a new NIA Program Project grant to study the impact of amyloid on brain aging. Dr. Sperling has received the American Academy of the Neurology Clinical Research Fellowship Award, the Harvard Medical School Scholars in Medicine Award, the Alzheimer’s Association Memory Ride Award, a Paul Beeson Faculty Scholars in Aging Award, and the 2007 American Academy of Neurology Research in Geriatric Neurology Award.